Saturday - April 19, 2025
Depemokimab applications accepted for review by the US FDA for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps (CRSwNP)
March 03, 2025
LONDON, England, March 3 [Category: BizPharmaceuticals] -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release:

* * *

Depemokimab applications accepted for review by the US FDA for asthma with type 2 inflammation and for chronic rhinosinusitis with nasal polyps (CRSwNP)

* If approved, depemokimab will be the first ultra-long-acting biologic with 6-month dosing

* Submissions based on data from positi . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products